What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.
Journal
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
ISSN: 1529-7535
Titre abrégé: Pediatr Crit Care Med
Pays: United States
ID NLM: 100954653
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
To present consensus statements and supporting literature for plasma and platelet product variables and related laboratory testing for transfusions in general critically ill children from the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding. Systematic review and consensus conference of international, multidisciplinary experts in platelet and plasma transfusion management of critically ill children. Not applicable. Critically ill pediatric patients at risk of bleeding and receiving plasma and/or platelet transfusions. None. A panel of 10 experts developed evidence-based and, when evidence was insufficient, expert-based statements for laboratory testing and blood product attributes for platelet and plasma transfusions. These statements were reviewed and ratified by the 29 Transfusion and Anemia EXpertise Initiative - Control/Avoidance of Bleeding experts. A systematic review was conducted using MEDLINE, EMBASE, and Cochrane Library databases, from inception to December 2020. Consensus was obtained using the Research and Development/University of California, Los Angeles Appropriateness Method. Results were summarized using the Grading of Recommendations Assessment, Development, and Evaluation method. We developed five expert consensus statements and two recommendations in answer to two questions: what laboratory tests and physiologic triggers should guide the decision to administer a platelet or plasma transfusion in critically ill children; and what product attributes are optimal to guide specific product selection? The Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding program provides some guidance and expert consensus for the laboratory and blood product attributes used for decision-making for plasma and platelet transfusions in critically ill pediatric patients.
Identifiants
pubmed: 34989701
doi: 10.1097/PCC.0000000000002854
pii: 00130478-202201001-00001
pmc: PMC8769352
mid: NIHMS1746603
doi:
Banques de données
ClinicalTrials.gov
['NCT02549222']
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1-e13Subventions
Organisme : NHLBI NIH HHS
ID : R13 HL154544
Pays : United States
Informations de copyright
Copyright © 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
Déclaration de conflit d'intérêts
Dr. Goel received funding from the National Heart, Lung, and Blood Institute and Rigel Pharmaceuticals. Dr. Nellis received support for article research from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Références
The Joint Commission and the American Medical Association-Convened Physician Consortium: National summit on overuse. Physician Consortium for Performance Improvement® (PCPI®) (Ed). In: Proceedings from the National Summit on Overuse, 2013. Available at: https://www.jointcommission.org/resources/news-and-multimedia/podcasts/take-5-blood-transfusions-blood-management--aryeh-shander-md-society-for-the-advancement-of-blood-ma/ . Accessed November 11, 2021
Slonim AD, Joseph JG, Turenne WM, et al. Blood transfusions in children: A multi-institutional analysis of practices and complications. Transfusion. 2008; 48:73–80
Goel R, Chappidi MR, Patel EU, et al. Trends in red blood cell, plasma, and platelet transfusions in the United States, 1993-2014. JAMA. 2018; 319:825–827
Bolton-Maggs PH. Bullet points from SHOT: Key messages and recommendations from the Annual SHOT Report 2013. Transfus Med. 2014; 24:197–203
Oakley FD, Woods M, Arnold S, et al. Transfusion reactions in pediatric compared with adult patients: A look at rate, reaction type, and associated products. Transfusion. 2015; 55:563–570
Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion. 2002; 42:556–566
Tobian AA, Savage WJ, Tisch DJ, et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion. 2011; 51:1676–1683
Du Pont-Thibodeau G, Tucci M, Ducruet T, et al. Survey on stated transfusion practices in PICUs. Pediatr Crit Care Med. 2014; 15:409–416
Lacroix J, Demaret P, Tucci M. Red blood cell transfusion: Decision making in pediatric intensive care units. Semin Perinatol. 2012; 36:225–231
Nellis ME, Karam O, Valentine S, et al.; Pediatric Critical Care Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Executive summary of recommendations and expert consensus for plasma and platelet transfusion practice in critically ill children: From the Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding (TAXI-CAB). Pediatr Crit Care Med. 2022; 23:33–50
Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924–926
Nellis ME, Levasseur J, Stribling J, et al. Bleeding scales applicable to critically ill children: A systematic review. Pediatr Crit Care Med. 2019; 20:603–607
Saini A, West AN, Harrell C, et al. Platelet transfusions in the PICU: Does disease severity matter? Pediatr Crit Care Med. 2018; 19:e472–e478
Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005; 105:4106–4114
Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010; 362:600–613
Stanworth SJ, Estcourt LJ, Powter G, et al.; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013; 368:1771–1780
Uhl L, Assmann SF, Hamza TH, et al. Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial. Blood. 2017; 130:1247–1258
Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood. 1985; 66:1105–1109
Kaufman RM, Djulbegovic B, Gernsheimer T, et al.; AABB. Platelet transfusion: A clinical practice guideline from the AABB. Ann Intern Med. 2015; 162:205–213
Paniccia R, Priora R, Liotta AA, et al. Platelet function tests: A comparative review. Vasc Health Risk Manag. 2015; 11:133–148
Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood. 2012; 120:748–760
New HV, Stanworth SJ, Gottstein R, et al. British Society for Haematology Guidelines on transfusion for fetuses, neonates and older children (Br J Haematol. 2016;175:784-828). Addendum August 2020. Br J Haematol. 2020; 191:725–727
Goel R, Patel EU, White JL, et al. Factors associated with red blood cell, platelet, and plasma transfusions among inpatient hospitalizations: A nationally representative study in the United States. Transfusion. 2019; 59:500–507
Kahn S, Chegondi M, Nellis ME, et al. Overview of plasma and platelet transfusions in critically ill children. Front Pediatr. 2020; 8:601659
Karam O, Demaret P, Duhamel A, et al.; PlasmaTV investigators. Factors influencing plasma transfusion practices in paediatric intensive care units around the world. Vox Sang. 2017; 112:140–149
Karam O, Tucci M, Combescure C, et al. Plasma transfusion strategies for critically ill patients. Cochrane Database Syst Rev. 2013: CD010654
Kozek-Langenecker S. Clinical efficacy of fresh frozen plasma compared with coagulation factor concentrates for treating coagulopathy in patients with massive bleeding. Med Intensiva. 2016; 40:371–373
Saarinen UM, Koskimies S, Myllylä G. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang. 1993; 65:286–292
Trial to Reduce Alloimmunization to Platelets Study. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997; 337:1861–1869
Ronghe MD, Foot AB, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol. 2002; 118:1124–1127
Blajchman MA, Goldman M, Freedman JJ, et al. Proceedings of a consensus conference: Prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 2001; 15:1–20
Pruss A, Kalus U, Radtke H, et al. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfus Apher Sci. 2004; 30:41–46
Wang RR, Triulzi DJ, Qu L. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets. Am J Clin Pathol. 2012; 138:255–259
Yanagisawa R, Shimodaira S, Sakashita K, et al. Factors related to allergic transfusion reactions and febrile non-haemolytic transfusion reactions in children. Vox Sang. 2016; 110:376–384
Reid ME, Lomas-Francis C, Olsson ML. The Blood Group Antigen FactsBook, 3rd Edition, London, Elsevier, 2012
Cid J, Harm SK, Yazer MH. Platelet transfusion - the art and science of compromise. Transfus Med Hemother. 2013; 40:160–171
Molnar R, Johnson R, Sweat LT, et al. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion. 2002; 42:177–182
Poston JN, Sugalski J, Gernsheimer TB, et al. Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: A survey of NCCN® centres. Vox Sang. 2020; 115:334–338
Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother. 2011; 38:65–70
Klein HG. Pathogen inactivation technology: Cleansing the blood supply. J Intern Med. 2005; 257:224–237
Hacquard M, Lecompte T, Belcour B, et al. Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang. 2012; 102:354–361
Spinella PC, Frazier E, Pidcoke HF, et al. All plasma products are not created equal: Characterizing differences between plasma products. J Trauma Acute Care Surg. 2015; 78:S18–S25
Toussaint-Hacquard M, Coppo P, Soudant M, et al. Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: A French retrospective multicenter cohort study. Transfusion. 2015; 55:2445–2451
Bartelmaos T, Chabanel A, Léger J, et al. Plasma transfusion in liver transplantation: A randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion. 2013; 53:1335–1345
Camazine MN, Karam O, Colvin R, et al.; PlasmaTV Investigators. Outcomes related to the use of frozen plasma or pooled solvent/detergent-treated plasma in critically ill children. Pediatr Crit Care Med. 2017; 18:e215–e223
Pidcoke HF, Spinella PC, Ramasubramanian AK, et al. Refrigerated platelets for the treatment of acute bleeding: A review of the literature and reexamination of current standards. Shock. 2014; 41(suppl 1):51–53
Gathof BS, Tauszig ME, Picker SM. Pathogen inactivation/reduction of platelet concentrates: Turning theory into practice. ISBT Sci Ser. 2010; 5:114–119
Amotosalen: Allogeneic cellular immunotherapies system, INTERCEPT plasma system, INTERCEPT platelet system, S 59. BioDrugs. 2003; 17:66–68
Schulz WL, McPadden J, Gehrie EA, et al. Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. J Pediatr. 2019; 209:220–225
Jimenez-Marco T, Garcia-Recio M, Girona-Llobera E. Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: Focusing on neonates. Transfusion. 2019; 59:3580–3588
van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: A randomized controlled trial. Blood. 2018; 132:223–231
Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017; 7:CD009072
Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev. 2020; 34:250–257
Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: Correlation with bleeding and survival. Transfusion. 2008; 48:1959–1965
Meehan KR, Matias CO, Rathore SS, et al. Platelet transfusions: Utilization and associated costs in a tertiary care hospital. Am J Hematol. 2000; 64:251–256
Lieberman L, Callum J, Cohen R, et al. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: A single center cohort study. Transfusion. 2020; 60:2537–2546
Hess JR, Trachtenberg FL, Assmann SF, et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang. 2016; 111:281–291
Embaby MM, Rangarajan HG, Abu-Arja R, et al. Refractory thrombocytopenia is a valid early diagnostic criteria for hepatic veno-occlusive disease in children. Biol Blood Marrow Transplant. 2020; 26:546–552
Cohn CS. Platelet transfusion refractoriness: How do I diagnose and manage? Hematology Am Soc Hematol Educ Program. 2020; 2020:527–532
Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin North Am. 2016; 30:665–677
Rioux-Massé B, Cohn C, Lindgren B, et al. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion. 2014; 54:3080–3087
Nellis ME, Remy KE, Lacroix J, et al.; the Pediatric Critical Care Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding (TAXI-CAB) in collaboration with the Pediatric Critical Care Blood Research Network (BloodNet) and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Research Priorities for Plasma and Platelet Transfusion Strategies in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative–Control/Avoidance of Bleeding (TAXI-CAB). Pediatr Crit Care Med. 2022; 23:e63–e73